Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
EU chief urges Iran to free imprisoned protesters, lift internet ban - 2Big Bear glows with big stars | Space photo of the day for Dec. 31, 2025
- 3Key takeaways from Sen. Bill Cassidy's interview on 'Face the Nation' with Margaret Brennan
- 4Tyler Childers' 'Snipe Hunt' 2026 Tour: How to get tickets, presale times, prices and more
- 5Study finds humans were making fire 400,000 years ago, far earlier than once thought
- Yasser Abu Shabab's killing raises questions about Israel's militia strategy in Gaza
- Seven deaths possibly linked to malfunctioning glucose monitors
- New COVID-19 variant 'Cicada' is spreading. What to know about BA.3.2.
- Ocean side Objections: Staggering Waterfront Breaks
- Supreme Court case about ‘crisis pregnancy centers’ highlights debate over truthful advertising standards
- There are thousands of aligned holes in Peru. Archaeologists now think they know who made them
- Massive supernova explosion may have created a binary black hole
- Pick Your Favored kind of books
- Fireballs and a full moon. Here’s how to see two celestial events this week
